Form 4: Prestige Healthcare Director Receives RSU Compensation

Prestige Consumer Healthcare Inc. director James D'Arecca received 2,094 restricted stock units valued at $155,000 as part of the company's director compensation program.

Summary

• Director James D'Arecca of Prestige Consumer Healthcare Inc. (PBH) acquired 2,094 restricted stock units (RSUs).
• The RSUs were granted on August 5, 2025, as part of the Issuer's director compensation program.
• The total value of the compensation in RSUs is $155,000.
• The RSUs were calculated based on a closing stock price of $674.04 on the grant date.
• Following this transaction, James D'Arecca beneficially owns 6,591 shares of common stock.

Sentiment

Score: 7

Explanation: The filing indicates a routine, positive corporate governance action where a director's interests are further aligned with shareholders through equity compensation. There are no negative financial implications or red flags, making the sentiment generally positive and expected.

Positives

• The grant of restricted stock units aligns the director's interests with those of shareholders, promoting long-term value creation.
• The compensation program helps attract and retain qualified board members.

Risks

• The value of the restricted stock units is subject to the future performance of Prestige Consumer Healthcare Inc.'s common stock.
• Vesting of the RSUs is contingent on the director's continued service for one year, or specific events like death, separation, or change in control.

Future Outlook

The restricted stock units are scheduled to vest on the first anniversary of the grant date, August 5, 2026. Settlement of the vested units will occur promptly following the earliest of the director's death, separation from service, or a change in control of the company.

Industry Context

Director compensation through equity awards like restricted stock units is a common practice across industries, particularly in consumer healthcare, to align the interests of board members with long-term shareholder value. This practice is standard for publicly traded companies.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) for director compensation is a widely adopted practice, aligning with corporate governance best practices seen in companies like Johnson & Johnson (JNJ) or Procter & Gamble (PG), which often use equity-based awards to incentivize long-term performance and retention of their board members.
• The vesting period of one year is typical for such grants, ensuring continued commitment from the director.
• The settlement triggers (death, separation, change in control) are standard provisions designed to manage the distribution of vested equity in various scenarios.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to James D'Arecca, a director, constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The equity compensation aligns the director's financial interests with shareholders, potentially leading to better long-term decision-making aimed at increasing share value.

Next Steps

• The restricted stock units are expected to vest on August 5, 2026.
• Settlement of the vested units will occur upon the earliest of the director's death, separation from service, or a change in control.

Key Dates

Recommendation

This Form 4 filing details a routine director compensation event, which is a standard corporate governance practice. It does not contain information that would fundamentally alter the investment thesis for Prestige Consumer Healthcare Inc. (PBH), nor does it reveal any significant new financial performance data or strategic shifts. Therefore, it provides no basis for a change in an existing investment position, leading to a 'hold' recommendation.

Keywords

Prestige Consumer Healthcare, PBH, SEC Form 4, Restricted Stock Units, RSU, Director Compensation, Insider Trading, Equity Compensation, Corporate Governance